Fig. 6.

Dual mTORC1/C2 kinase/MEK inhibition suppresses angiogenesis in vivo and inhibits the FAK/SRC complex. (A) Western blot of tumor lysates for endothelial markers with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as loading control. (B) HUVECs were treated with TAK228, trametinib, and combination at 10 nM concentration for 6 hours. DMSO was included as vehicle control. Western blot in the left panel shows decreased activation of FAK and SRC. β-actin is the loading control. Numbers above the blot indicate the densitometry compared with vehicle control.